Navigation Links
Soluble IL-4 Receptor - A new boon for asthmatics

Bronchial asthma, the disease which is never an easy combat for any practising physician, is now being avenged by a new drug. A soluble interleukin-4 receptor (IL-4R), which acts as an IL-4 antagonist, appears to be safe and effective in preventing a decline in lung function and in preventing asthma symptoms.

In their study, Dr. Larry C. Borish, from the University of Virginia Health Sciences Center in Charlottesville, and colleagues randomly selected 62 patients with symptoms pertaining to moderate persistent asthma. They were stopped from inhaling corticosteroids and were divided into two groups. In one group IL-4 receptor were given and to the other group placebo was given.

It was found that, after a 12-week trial, those in the IL-4R group,there was no decline in FEV1; however, lung function did decline among those receiving placebo.

This study is "the demonstrate the potential clinical efficacy of a TH2 inhibitor for the treatment of asthma," the investigators note.

This soluble IL-4 receptor, which isn't a corticosteroid, selectivelyinhibits allergic mechanisms will be a new boon in the treatment strategy of asthma.

"These data demonstrate the critical role of IL-4 in the pathogenesis of asthma and the potential benefit of this approach to therapy," Dr. Borish and colleagues conclude.

Page: 1

Related medicine news :

1. Soluble Ingredient Can Make Fatty Fast Foods Healthier
2. Toll-like Receptor (Tlr3) Attachment Leads To Lethal Encephalitis
3. Genetic Variation In Bitter-Taste Receptor Gene Increases Alcoholic Risk
4. Calcium Receptor Vital For Stem Cell Migration to Bone Marrow
5. Researchers Identify Lung Failure Therapy Receptor
6. Effects Of Certain Food Related To Single Pain Receptors
7. Receptor for H.pylori Identified in Stomach
8. Functional Differences In Estrogen Receptor Could Be A Therapeutic Target
9. Schizophrenia Complicates With Altered Receptor Activity
10. Definite Connection Between Receptor Levels and Cocaine Abuse Reveals PET Imaging
11. Aromatase Inhibitors Better Than Tamoxifen For Treating Receptor-Positive Early Breast Cancer
Post Your Comments:

(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, I ... Bronx, N.Y. “I thought there had to be a convenient and comfortable way to ... The PROTECTOR enables disabled individuals to safely travel during cold or inclement weather. In ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... philanthropic seniors, is resulting in a way for homeless people to have a ... have launched a new initiative whereby they are repurposing plastic bags into sleeping ...
(Date:11/25/2015)... ... November 25, 2015 , ... Since its launch in 2012, ... adult stem cell therapies to patients with chronic degenerative medical conditions. Now, the ... Registered Trademark (RTM). , Organizations are required to hold a registered trademark in ...
(Date:11/24/2015)... ... November 25, 2015 , ... Genesis Chiropractic Software ... software creates an agreement between the practice owner and the patient that automatically ... notification, and projections. Click here to learn more. , ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... FRANCISCO , Nov. 24, 2015  Thanks to ... Dignity Health St. Mary,s Medical Center,s Sister Diane Grassilli ... breast imaging capabilities in San Francisco ... an anonymous friend, stepped forward with a gift of ... for Breast Digital Mammography with Tomosynthesis and Whole Breast ...
(Date:11/24/2015)... Colo. , Nov. 24, 2015  Array ... that its Chief Executive Officer, Ron Squarer ... Healthcare Conference in New York.  The public is ... webcast on the Array BioPharma website.Event:Piper Jaffray Annual ... , Wednesday, December 2, 2015Time:1:30 p.m. Eastern Time ...
(Date:11/24/2015)... HOUSTON, TX and VANCOUVER, Nov. 24, 2015 /PRNewswire/ ... EPI; NASDAQ: EPIX ) announced today that the ... clinical study of EPI-506 as a treatment for metastatic ... States and Canada.  --> ... --> In the Phase 1/2 clinical trial, ...
Breaking Medicine Technology: